TY - JOUR
T1 - The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol
AU - Thorp, Micah
AU - Demattos, Angelo
AU - Bennett, William
AU - Barry, John
AU - Norman, Douglas
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2000/3/27
Y1 - 2000/3/27
N2 - The use of cyclosporine for immunosuppression in renal transplantation allograft recipients is associated with hypertrichosis, gingival hyperplasia, and hypercholesterolemia. Conversion of patients to tacrolimus may lead to an improvement in these effects with minimal risk of rejection or allograft dysfunction. Methods. Sixteen renal transplant recipients were prospectively converted from CsA to tacrolimus and followed for 1 year. Gingival hyperplasia index, total cholesterol, and blood pressure were recorded at the outset, 4-, 8-, and 12-month intervals. Glomerular filtration rate was checked before conversion and 1 year later. Photographs documenting hypertrichosis were taken before conversion and 1 year later. Adverse effects from tacrolimus were recorded at 4, 8, and 12 months. Results. Twelve patients with hypertrichosis noted rapid improvement. Mean gingival hyperplasia index decreased from 24 to 6; mean total cholesterol decreased from 237 to 195. Glomerular filtration rate was essentially unchanged (56 to 54). One episode of rejection occurred, three patients developed diarrhea, three noted headaches, and one had a tremor. Conclusion. If carefully monitored, patients suffering adverse effects secondary to cyclosporine may be converted to tacrolimus with minimal risk of allograft dysfunction or rejection.
AB - The use of cyclosporine for immunosuppression in renal transplantation allograft recipients is associated with hypertrichosis, gingival hyperplasia, and hypercholesterolemia. Conversion of patients to tacrolimus may lead to an improvement in these effects with minimal risk of rejection or allograft dysfunction. Methods. Sixteen renal transplant recipients were prospectively converted from CsA to tacrolimus and followed for 1 year. Gingival hyperplasia index, total cholesterol, and blood pressure were recorded at the outset, 4-, 8-, and 12-month intervals. Glomerular filtration rate was checked before conversion and 1 year later. Photographs documenting hypertrichosis were taken before conversion and 1 year later. Adverse effects from tacrolimus were recorded at 4, 8, and 12 months. Results. Twelve patients with hypertrichosis noted rapid improvement. Mean gingival hyperplasia index decreased from 24 to 6; mean total cholesterol decreased from 237 to 195. Glomerular filtration rate was essentially unchanged (56 to 54). One episode of rejection occurred, three patients developed diarrhea, three noted headaches, and one had a tremor. Conclusion. If carefully monitored, patients suffering adverse effects secondary to cyclosporine may be converted to tacrolimus with minimal risk of allograft dysfunction or rejection.
UR - http://www.scopus.com/inward/record.url?scp=0034719672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034719672&partnerID=8YFLogxK
U2 - 10.1097/00007890-200003270-00029
DO - 10.1097/00007890-200003270-00029
M3 - Article
C2 - 10762229
AN - SCOPUS:0034719672
SN - 0041-1337
VL - 69
SP - 1218
EP - 1220
JO - Transplantation
JF - Transplantation
IS - 6
ER -